US Promises Climate Aid for 20 Developing Cities

USAID chief Samantha Power. EPA
USAID chief Samantha Power. EPA
TT

US Promises Climate Aid for 20 Developing Cities

USAID chief Samantha Power. EPA
USAID chief Samantha Power. EPA

The USAID chief on Wednesday promised support for two dozen developing cities to cope with climate change and announced more than $2 billion in new adaptation finance from the private sector, Agence France Press (AFP) reported.

Samantha Power, administrator of the US Agency for International Development, is visiting the COP28 climate summit in Dubai. USAID promised $53 million to help 23 cities in the developing world switch to low-carbon and climate-resilient activities, including electric vehicles.

Cities targeted include Kyrgyzstan's capital Bishkek, the western Indian city of Rajkot, the northeastern South African city of Mbombela, and Hermosillo and Merida in Mexico.

Urban areas are responsible for three-quarters of global carbon emissions. USAID also announced the mobilization of another $2.3 billion in private-sector investment as part of an initiative by President Joe Biden to initiatives such as early-warning systems, climate-resilient food infrastructure and new financial products.

Twenty-one companies have newly committed funding through the initiative, dubbed the President's Emergency Plan for Adaptation and Resilience, including IBM and Visa, USAID said, after 10 founding members joined last year at COP27 in Egypt.

Power, the latest senior US official to join lead negotiator John Kerry during the marathon talks, is focusing efforts on helping developing countries adapt to the changing climate.

"COP28 comes at the end of yet another year where people around the world saw their lives turned upside down by record-high temperatures and extreme weather -- from the catastrophic drought and now devastating flooding in the Horn of Africa to the hottest summer in Earth's recorded history," Power said.

"We must do more to address the climate crisis -- and we are," she said in a statement to AFP ahead of her arrival.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”